news-releases

Latest News

  • TapImmune Announces Reverse Stock Split in Prepara...

    JACKSONVILLE, Florida, September 15, 2016 / TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and...

    Read more

  • TapImmune Issues Update: Multiple Phase 2 Trials, ...

    JACKSONVILLE, Florida, September 6, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and...

    Read more

  • TapImmune Appoints Michael J. Loiacono as Chief Fi...

    Accomplished Financial Director & CFO of Public Companies August 25, 2016, Jacksonville, FL,, TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immuno-oncology company specializing in the...

    Read more

  • TAPIMMUNE RECOGNIZES MARY WASHBURN BINKLEY, HER FA...

    Mary lives her life through her Christian faith, dedication to her family and through service to others. She is an alumni of the University of Tennessee, Knoxville, and her family are avid Tennessee...

    Read more

  • TapImmune Enters into Definitive Agreements to rai...

    Company has Applied for Listing on Nasdaq Capital Market JACKSONVILLE, Florida, August 11, 2016 / TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of...

    Read more

  • Tampa executive takes key post at a Jacksonville b...

    A bioscience veteran in Tampa has been named president and chief operating officer of TapImmune Inc., a Jacksonville company developing a vaccine to treat cancer. John Bonfiglio — formerly the...

    Read more

  • TapImmune Appoints Dr. John N. Bonfiglio as Presid...

    JACKSONVILLE, Florida, July 19, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and...

    Read more

  • Q&A with TapImmune CEO Dr. Glynn Wilson, on a...

    A vaccine that can prevent the recurrence and metastasis of cancer would save countless lives. In the past century, vaccines have virtually eradicated life threatening diseases including polio and...

    Read more

  • TapImmune Doses First Patient in its Phase 2 Tripl...

    Cancer vaccine TPIV 200 to be evaluated in four Phase 2 trials in 2016 JACKSONVILLE, FL, June 21, 2016 / TapImmune,Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the...

    Read more

  • TAPIMMUNE ANNOUNCES FINALIZATION OF LICENSE AGREEM...

     Agreement Will Allow for the Transfer of IND from Mayo to TapImmune and the Initiation of Company-Sponsored Phase 2 Clinical Trials Jacksonville FL, June 7, 2016 – TapImmune, Inc. (OTCQB:...

    Read more

  • TapImmune to Present at the LD Micro Invitational ...

    JACKSONVILLE, FL, June 6, 2016 / TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines...

    Read more

  • TapImmune to Present at SeeThruEquity and Marcum C...

    TapImmune,Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer &...

    Read more

  • TapImmune to Present at the 3rd Annual Growth Capi...

    JACKSONVILLE, FL, April 28, 2016 / TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines...

    Read more

  • TapImmune Announces Phase 2 Ovarian Cancer Trial S...

    JACKSONVILLE, Florida, April 21, 2016 /PRNewswire/ – Study to commence Q2 2016 at Sloan Kettering Institute Cancer vaccine and checkpoint inhibitor combination to be evaluated in...

    Read more

  • TapImmune Completes GMP Manufacturing and Release ...

    Doses for use at Mayo Clinic and other clinical sites Stable, easily reconstituted product contains five folate receptor alpha peptides in a single vial TapImmune, Inc. (TPIV), a clinical-stage...

    Read more

  • Join TapImmune at Jacksonville’s Immunothera...

    UPCOMING EVENT Jacksonville’s Immunotherapy Development Program The BioFlorida Northeast Chapter – Jacksonville has put together a program at Mayo Clinic focusing on the partnership...

    Read more

  • Experts say research shows promise for a breast ca...

    03/31/16 Medicine By Kathleen McGrory, Times staff writer There are vaccines to help the body fight off measles, mumps and the flu. But breast cancer? That’s exactly the technology a...

    Read more

  • Update with TapImmune, Inc. – Discusses Targ...

    LOS ANGELES, CA–(Marketwired – March 17, 2016) – StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Glynn Wilson, Ph.D.,...

    Read more

  • StockNewsNow.com Publishes New SNNLive Video Inter...

    LOS ANGELES, CA–(Marketwired – March 17, 2016) – StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Glynn Wilson, Ph.D.,...

    Read more

  • StockNewsNow.com Publishes New SNNLive Video Inter...

      LOS ANGELES, CA–(Posted on Marketwired – March 17, 2016) – StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Glynn...

    Read more

23 Nov 2015

TapImmune CEO, Glynn Wilson speaks with CBS 12′s Lynda Figueredo

Trials underway to test vaccine against several cancers Story by Lynda Figueredo/CBS12 For the first time ever, a Palm Beach County doctor is on the verge of one of the biggest medical breakthroughs of the century. The statewide clinical trials are for a vaccine that prevents breast, ovarian and...

more >

5 Nov 2015

Immuno-Oncology Company, TapImmune Inc., Moves Corporate Headquarters to Jacksonville Florida

Clinical-Stage Developer of Vaccines for Cancer & Metastatic Disease moves into closer proximity to collaborators at Mayo Clinic in Jacksonville JACKSONVILLE, Florida, November 5, 2015 /PRNewswire/ – TapImmune Inc., (TPIV) a clinical-stage immune-oncology company specializing in the...

more >

13 Oct 2015

TapImmune to Present at Dawson James Small Cap Growth Conference in Florida on October 15, 2015

JACKSONVILLE, Florida, October 13, 2015 /PRNewswire TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, will be a featured...

more >

7 Oct 2015

TapImmune to Present at Aegis Capital 2015 Growth Conference in Las Vegas on October 9, 2015

JACKSONVILLE, Florida, October 7, 2015 /PRNewswire/ – TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, will be featured as a...

more >

28 Sep 2015

SeeThruEquity Issues Company Update on TapImmune Highlighting Clinical Program Updates and Recent Financing

NEW YORK, NY / ACCESSWIRE / September 28, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (TPIV). The note is available here: TPIV Update...

more >

15 Sep 2015

TapImmune Vaccine to be Studied in a $13.3 Million U.S. Department of Defense Grant to Mayo Clinic for Phase II Clinical Trial in Triple Negative Breast Cancer

Trial will Utilize Folate Receptor Alpha Vaccine Licensed to TapImmune for Commercialization TapImmune, Inc. (TPIV), congratulates Mayo Clinic for being awarded a grant of $13.3 million from the U.S. Department of Defense. This grant, commencing September 15, 2015, will cover the costs for a 280...

more >

12 Sep 2015

TapImmune Director to Represent Great Britain In Triathlon World Championships

TapImmune congratulates Director David Lasko-Pooley on being selected to represent Great Britain in the “2015 ITU World Triathlon Grand Final and World Championships to be held in Chicago, IL, starting on September 15, 2015.   This event is also part of qualification for some countries for the...

more >

18 Aug 2015

TapImmune Completes Transfer of IND From The Mayo Clinic

Significant Milestone Marks The Next Major Step in Beginning Phase 2 Trials in Cancer Using The Folate Receptor Alpha Peptide Vaccine Technology SEATTLE, Wash., Aug. 18, 2015 /PRNewswire/ –TapImmune, Inc. (TPIV),  a clinical stage immunotherapy company, specializing in the development of...

more >

23 Jun 2015

TapImmune Reports Robust Immune Responses Generated in 19 of 20 Evaluable HER2/neu Breast Cancer Patients

Phase I Trial analyses shows safety and positive immune response data SEATTLE, June 23, 2015 /PRNewswire/ – TapImmune Inc. (TPIV) is pleased to report the completion of data analysis from patients treated in a Phase I clinical trial. In this Phase 1 trial conducted at the Mayo Clinic in...

more >

Page 1 of 212